Document:

Exhibit 10.2

 

 

 

January
2, 2013

 

 

Mr. David R. Crockford

62 Kent Street

Newburyport, MA 01950

 

		Re:	First Amendment to Temporary Employment Terms

 

Dear David:

 

This
letter agreement (the “Amendment”) amends certain of the terms and conditions relating to your employment with
RegeneRx Biopharmaceuticals, Inc. ( “Company”) that were set forth in that Temporary Employment Terms
Letter Agreement dated July 2, 2012, executed by you and the Company (collectively, the “Employment Agreement”).
As provided at the end of this letter, you may accept this Amendment by signing and returning to us a counterpart copy of this
letter, which signature and return will result in this Amendment being binding between the Company and you as to the matters set
forth herein, as of January 1, 2013 (the “Effective Date”). Defined terms that are not defined herein shall
have the meaning assigned to them in the Employment Agreement.

 

1.The Employment Agreement
shall be amended by replacing the date of “December 31, 2012” throughout the Employment Agreement with “June
30, 2013.”

 

2.The second to the last
paragraph of the Employment Agreement is hereby amended and restated in its entirety as follows:

 

By signing this letter, you acknowledge
that the terms described in this letter, together with the your Proprietary Information, Non-Competition and Inventions Assignment
Agreement, set forth the entire understanding between us and supersede any other representations or agreements, whether written
or oral, including, but not limited to your Second Amended and Restated Employment Agreement dated March 12, 2009, as amended;
there are no terms, conditions, representations, warranties or covenants other than those contained herein. No term or provision
of this letter may be amended waived, released, discharged or modified except in writing, signed by you and an authorized officer
of the Company, except that the Company may, in its sole discretion, adjust salaries, incentive compensation, stock plans, benefits,
job titles, locations, duties, responsibilities, and reporting relationships. The parties have entered into a separate Amended
and Restated Change in Control Agreement between you and Company dated July 2, 2012 (the “CIC Agreement”). This separate
agreement governs other aspects of the relationship between the parties, has or may have provisions that survive termination of
your employment under this Agreement, may be amended or superseded by the parties without regard to this Agreement, and is enforceable
according to its terms without regard to the enforcement provision of this Agreement. Pursuant
to Section 8 of the CIC Agreement, the parties agree to extend the deadline to consummate a Change in Control from December
31, 2012, to June 30, 2013. 

 

 

RegeneRx
Biopharmaceuticals, Inc. ·
15245 Shady Grove Road, Suite 470, Rockville, MD 20850

PHONE
301.208.9191 ·
FAX 301.208.9194 ·
WEB www.regenerx.com

   

    	 

    	 	

    
  

3.Except
as herein modified or amended, no other term or provision of the Employment Agreement is amended or modified in any respect. Nothing
in this Amendment is intended to alter the at-will nature of your employment with the Company.

 

4.This Amendment,
together with your Employment Agreement and its exhibits (as expressly modified herein), constitute the complete, final and exclusive
embodiment of the entire agreement between the Company and you with regard to matters set forth herein, and supersede and replace
any other agreements (whether written or unwritten) you may have with the Company with regard to matters set forth herein. This
Amendment will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit
of both you and the Company, their heirs, successors and assigns. If any provision of this Amendment is determined to be invalid
or unenforceable, in whole or in part, this determination shall not affect any other provision of this Amendment and the provision
in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as
possible under applicable law. This Amendment may be executed in counterparts which shall be deemed to be part of one original,
and facsimile signatures shall be equivalent to original signatures.

 

To indicate your understanding and acceptance
of this Amendment, please sign and date below, and return this Amendment to me. You may retain the enclosed additional copy of
this Amendment for your files.

 

Sincerely,

 

RegeneRx Biopharmaceuticals, Inc.

 

		By:	/s/_J.J. Finkelstein

Name: J.J. Finkelstein

Title: President & CEO

 

 

Agreed to and Accepted:

 

 

/s/_David R. Crockford

David R. Crockford

 

January 2, 2013

DateExhibit 10.3

 

 

 

January
2, 2013

 

 

Dr. Allan L. Goldstein

P.O. Box 29

Reedville,Va 22539

 

		Re:	First Amendment to Temporary Employment Terms

 

Dear Allan:

 

This
letter agreement (the “Amendment”) amends certain of the terms and conditions relating to your employment with
RegeneRx Biopharmaceuticals, Inc. ( “Company”) that were set forth in that Temporary Employment Terms
Letter Agreement dated July 2, 2012, executed by you and the Company (collectively, the “Employment Agreement”).
As provided at the end of this letter, you may accept this Amendment by signing and returning to us a counterpart copy of this
letter, which signature and return will result in this Amendment being binding between the Company and you as to the matters set
forth herein, as of January 1, 2013 (the “Effective Date”). Defined terms that are not defined herein shall
have the meaning assigned to them in the Employment Agreement.

 

1.The Employment Agreement
shall be amended by replacing the date of “December 31, 2012” throughout the Employment Agreement with “June
30, 2013.”

 

2.The second to the last
paragraph of the Employment Agreement is hereby amended and restated in its entirety as follows:

 

By signing this letter, you acknowledge
that the terms described in this letter, together with the your Proprietary Information, Non-Competition and Inventions Assignment
Agreement, set forth the entire understanding between us and supersede any other representations or agreements, whether written
or oral, including, but not limited to your Second Amended and Restated Employment Agreement dated March 12, 2009, as amended;
there are no terms, conditions, representations, warranties or covenants other than those contained herein. No term or provision
of this letter may be amended waived, released, discharged or modified except in writing, signed by you and an authorized officer
of the Company, except that the Company may, in its sole discretion, adjust salaries, incentive compensation, stock plans, benefits,
job titles, locations, duties, responsibilities, and reporting relationships. The parties have entered into a separate Amended
and Restated Change in Control Agreement between you and Company dated July 2, 2012 (the “CIC Agreement”). This separate
agreement governs other aspects of the relationship between the parties, has or may have provisions that survive termination of
your employment under this Agreement, may be amended or superseded by the parties without regard to this Agreement, and is enforceable
according to its terms without regard to the enforcement provision of this Agreement. Pursuant
to Section 8 of the CIC Agreement, the parties agree to extend the deadline to consummate a Change in Control from December
31, 2012, to June 30, 2013.

 

 

 

RegeneRx
Biopharmaceuticals, Inc. ·
15245 Shady Grove Road, Suite 470, Rockville, MD 20850

PHONE
301.208.9191 ·
FAX 301.208.9194 ·
WEB www.regenerx.com

   

    	 

    	 	

    
 

 

3.Except
as herein modified or amended, no other term or provision of the Employment Agreement is amended or modified in any respect. Nothing
in this Amendment is intended to alter the at-will nature of your employment with the Company.

 

4.This Amendment,
together with your Employment Agreement and its exhibits (as expressly modified herein), constitute the complete, final and exclusive
embodiment of the entire agreement between the Company and you with regard to matters set forth herein, and supersede and replace
any other agreements (whether written or unwritten) you may have with the Company with regard to matters set forth herein. This
Amendment will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit
of both you and the Company, their heirs, successors and assigns. If any provision of this Amendment is determined to be invalid
or unenforceable, in whole or in part, this determination shall not affect any other provision of this Amendment and the provision
in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as
possible under applicable law. This Amendment may be executed in counterparts which shall be deemed to be part of one original,
and facsimile signatures shall be equivalent to original signatures.

 

To indicate your understanding and acceptance
of this Amendment, please sign and date below, and return this Amendment to me. You may retain the enclosed additional copy of
this Amendment for your files.

 

Sincerely,

 

RegeneRx Biopharmaceuticals, Inc.

 

		By:	/s/_J.J. Finkelstein

Name: J.J. Finkelstein

Title: President & CEO

 

 

Agreed to and Accepted:

 

 

/s/_Allan L. Goldstein

Allan L. Goldstein

 

January 2, 2013

DateExhibit 10.1

 

EXTENSION OF EMPLOYMENT AGREEMENT

 

EXTENSION OF EMPLOYMENT AGREEMENT (this
“Extension”), dated as of January 8, 2013, by and between ZIOPHARM Oncology, Inc., a Delaware corporation with
principal executive offices at 1180 Avenue of the Americas, New York, NY 10036 (the “Company”), and JONATHAN
J. LEWIS, M.D., Ph.D., residing at 1522 Fairfield Beach Road, Fairfield, CT 06824 (the “Executive”). All capitalized
terms set forth herein shall (unless otherwise defined herein) have the meanings given to them in the Agreement (as defined below).

 

W I T N E S S E T H:

 

WHEREAS, the Company and Executive are parties
to that certain Employment Agreement dated January 8, 2008 (the “Agreement”).

 

WHEREAS, the extended Term of the Agreement
is scheduled to expire on January 8, 2013, and the Company and Executive each desire that Executive’s employment with the
Company continue to be governed by terms and conditions of the Agreement for a period of an additional one year, which period
may be further extended by mutual written agreement of Executive and the Company following further deliberations among Executive
and the Company’s Board of Directors (or, if applicable, the Compensation Committee thereof).

 

NOW, THEREFORE, in consideration of the
mutual covenants and agreements herein contained, the parties hereby agree as follows:

 

1.Extension of Term. The “Term” of
Executive’s employment under the Agreement shall be extended for a period of one (1) year expiring on January 8, 2014, which
period may be further extended by mutual written agreement of Executive and the Company following further deliberations among Executive
and the Company’s Board of Directors (or, if applicable, the Compensation Committee thereof).

 

2.No Other Modification. The agreement shall
not be otherwise modified by this Extension in any respect except as expressly set forth therein.

 

3.Counterparts. This Extension may be executed
in any number of counterparts, each of which shall constitute an original, but all of which together shall constitute one and the
same instrument.

 

4.Governing Law. This Extension shall be governed
by, and construed and interpreted in accordance with, the laws of the State of New York, without giving effect to its principles
of conflicts of laws.

 

The remainder of this page is intentionally
left blank

 

    	 

    	 	

    

 

IN WITNESS WHEREOF, the parties have executed
this Extension as of the date first above written.

 

	 	ZIOPHARM ONCOLOGY, INC.
	 	 
	 	 
	 	By: 	/s/ Caesar J. Belbel
	 	 	Caesar J. Belbel
Executive Vice President and Chief Legal Officer
	 	 	 
	 	 	 
	 	EXECUTIVE
	 	 
	 	/s/ Jonathan J. Lewis
	 	Jonathan J. Lewis, M.D., Ph.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}]]